HC Wainwright Issues Pessimistic Estimate for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.57) per share for the quarter, down from their previous forecast of ($0.24). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.65) EPS and FY2027 earnings at ($0.54) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The firm had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%.

VNDA has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Zacks Research cut Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, Jefferies Financial Group raised their price target on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $13.63.

Vanda Pharmaceuticals Trading Down 5.6%

NASDAQ:VNDA opened at $5.76 on Thursday. The firm has a market capitalization of $340.47 million, a P/E ratio of -1.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.39 and a quick ratio of 2.38. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $9.60. The company’s 50-day simple moving average is $7.32 and its 200 day simple moving average is $5.74.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC purchased a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth $25,000. Russell Investments Group Ltd. increased its holdings in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares in the last quarter. CWM LLC raised its position in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 7,575 shares during the last quarter. Quarry LP bought a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $53,000. Finally, Cerity Partners LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $69,000. Institutional investors own 88.14% of the company’s stock.

Key Headlines Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Wall Street bullishness around the upcoming PDUFA for Bysanti — analysts and models show large upside if the FDA approves the bipolar/schizophrenia treatment, which is keeping speculative demand alive. FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck
• Positive Sentiment: Brokerage consensus remains above neutral — some coverage still labels VNDA a buy or “moderate buy,” supporting a baseline of institutional interest ahead of the regulatory decision. Vanda Pharmaceuticals Inc. Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Trading was temporarily halted today for “VNDA” citing “News pending” — a pause that often precedes a material corporate or regulatory update and can amplify volatility when trading resumes.
• Neutral Sentiment: Widespread media attention: coverage and “buzz” ahead of the FDA verdict are driving elevated volume and short‑term momentum trading; that creates heightened risk/reward but not a clear directional signal until the decision. Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $22 price target but issued large downward revisions to near‑term EPS estimates — a mixed signal that keeps upside narratives alive while flagging weaker near‑term profitability. HC Wainwright analyst notes on Vanda
• Negative Sentiment: Zacks Research downgraded VNDA from “strong‑buy” to “hold,” signaling reduced conviction among some sell‑side analysts and likely contributing to downward pressure. Zacks Research downgrade
• Negative Sentiment: HC Wainwright sharply cut FY2026 and quarterly EPS forecasts (materially worsening loss projections), increasing concern about near‑term cash flow and execution if Bysanti or other catalysts don’t offset the shortfall. HC Wainwright EPS revisions
• Negative Sentiment: Analyst commentary framing VNDA as a “high‑risk” trade ahead of PDUFA emphasizes downside risk if the FDA rejects or requests more data — this narrative pressures risk‑averse investors and may amplify selling. Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.